An official website of the United States government
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
Trial Status: active
The goal of this clinical trial is to define a safe and effective dose of CRB-701 for
participants with solid tumors that are expressing a protein called nectin-4.
The main questions it aims to answer are:
What is the the safe and effective dose of CRB-701? What cancers can be treated
effectively with CRB-701?
Participants will be asked to attend clinic and be given a intravenous infusion of
CRB-701. They will have blood tests, CT or MRI Scans, and other assessments to measure
whether CRB-701 has an effect on tumors.
Inclusion Criteria
Confirmed diagnosis of select advanced or metastatic nectin-4 expressing solid tumors that have progressed having exhausted all appropriate lines of therapy or have no other standard therapy with proven clinical benefit. In Part C, HNSCC participants may enroll as first-line therapy.
Exclusion Criteria
Active of uncontrolled CNS metastases
History of solid tumors other than the diseases under study
History of and/or current cardiovascular events or conditions in the previous 6 months
